European Medicines Agency Recommends Restricting use of Pandemrix

Finalizing its review of Pandemrix and narcolepsy, the EMA’s Committee for Medicinal Products for Human Use (CHMP) recommended that in persons under 20 years of age, Pandemrix may only be used if the recommended seasonal trivalent influenza vaccine is not available and if immunisation against H1N1 is still needed.
EMA